MDxHealth SA (MDXH) Cash & Equivalents (2020 - 2024)

MDxHealth's Cash & Equivalents history spans 5 years, with the latest figure at $46.8 million for Q4 2024.

  • For Q4 2024, Cash & Equivalents rose 109.11% year-over-year to $46.8 million; the TTM value through Dec 2024 reached $46.8 million, up 109.11%, while the annual FY2024 figure was $46.8 million, 109.11% up from the prior year.
  • Cash & Equivalents for Q4 2024 was $46.8 million at MDxHealth, up from $22.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $58.5 million in Q4 2021 and bottomed at $15.5 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $22.4 million (2023), against an average of $31.8 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 266.69% in 2021 before it crashed 73.5% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $16.0 million in 2020, then surged by 266.69% to $58.5 million in 2021, then plummeted by 73.5% to $15.5 million in 2022, then surged by 44.36% to $22.4 million in 2023, then surged by 109.11% to $46.8 million in 2024.
  • Per Business Quant, the three most recent readings for MDXH's Cash & Equivalents are $46.8 million (Q4 2024), $22.4 million (Q4 2023), and $15.5 million (Q4 2022).